Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Dr. Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Luzhou People’s Hospital | China

Dr. Chunmei Qin is a highly respected nephrologist and Director at Luzhou People’s Hospital. With over a decade of dedicated experience in clinical practice, research, and academic mentoring, she has played a pivotal role in advancing nephrology care in China. Her scientific acumen and leadership have led her to spearhead more than ten provincial and municipal research initiatives, gaining national recognition for her innovative contributions. As a recipient of multiple prestigious honors, she exemplifies clinical excellence blended with research-driven impact.

Author Profile👤

Scopus

Strengths for the Awards✨

Dr. Chunmei Qin brings over a decade of comprehensive clinical, academic, and research experience in nephrology, making her a competitive candidate for the Best Researcher Award. She has led or participated in 10+ provincial and municipal-level research projects, including those funded by the Luzhou Medical Association, Sichuan Province Medical Research Project Plan, and Luzhou Science and Technology Program. Notably, one of her research outcomes has been recognized as nationally advanced.

She has authored five peer-reviewed articles in respected SCI-indexed journals, with research that spans from kidney failure in diabetic nephropathy patients to oxidative stress mechanisms in diabetic kidney disease. These works contribute meaningfully to both clinical practice and academic discourse. Additionally, she has received multiple accolades, including:

  • Outstanding Young Paper Award by the Sichuan Medical Association.

  • Outstanding Contribution Award by the Municipal Health Commission.

Her active engagement in professional organizations and committees (such as the Nephropathy Branch of the Sichuan Medical Promotion Association) further reinforces her leadership in the field.

🎓 Education

Dr. Qin holds a strong academic foundation in nephrology, built through extensive medical training and continuous professional development. Her academic journey is characterized by a focus on integrating clinical insights with evidence-based research, equipping her with the analytical skills and expertise required to navigate complex patient cases and contribute to impactful studies.

🏥 Experience

Currently serving as Director at Luzhou People’s Hospital, Dr. Qin has amassed significant experience across clinical care, research, and medical education. Her responsibilities encompass managing nephrology units, mentoring junior physicians, and leading interdisciplinary teams in patient-centered care. Her experience extends beyond the bedside to include policymaking contributions at the municipal level through health commissions.

🔬 Research Interests On Medicine and Health Sciences

Dr. Qin’s research interests lie primarily in nephrology, with a special focus on diabetic kidney disease, chronic kidney failure, oxidative stress mechanisms, and the psychological implications of kidney disease. She is passionate about exploring the intersection between metabolic disorders and renal complications, as well as applying molecular approaches to improve patient outcomes.

🏆 Awards

Dr. Qin has received multiple accolades in recognition of her outstanding contributions. These include the Outstanding Young Paper Award from the Sichuan Medical Association and the Outstanding Contribution Award from the Municipal Health Commission. Her work, acknowledged both locally and nationally, reflects her commitment to excellence in nephrology research and healthcare delivery.

📄 Publications

Dr. Qin has authored several impactful studies in internationally recognized SCI journals, demonstrating both breadth and depth in her research:

  1. Qin, C., Wu, Y., Zou, Y., et al. Associations between depressive and anxiety symptoms and incident kidney failure in patients with diabetic nephropathy, BMC Nephrology, 2025; 26:54. Cited by multiple nephrology scholars for its clinical relevance.

  2. Qin, C., Wang, Y., Zhao, L., et al. Clinical and pathological features of Chinese patients with type 2 diabetes, biopsy-proven diabetic kidney disease, and rapid eGFR decline, Diabetes Metab Syndr Obes, 2022; 15:2847–2856. Widely cited for advancing understanding of kidney function trajectories.

  3. Qin, C., Yin, D., Liu, F., et al. Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy: a case report, BMC Nephrology, 2023; 24(1):143. Referenced in case studies on rare renal pathologies.

  4. Zhang, R., Qin, C., Zhang, J., et al. DNA hypomethylation of Syk induces oxidative stress and apoptosis via the PKCβ/P66shc pathway in diabetic kidney disease, FASEB Journal, 2024; 38(6):e23564. Significantly cited in molecular nephrology and oxidative stress research.

  5. Qin, C., Li, G., Yuan, Y., et al. Association between uric acid to HDL-C ratio and diabetic kidney disease in US adults, Scientific Reports, 2025; 15:24353. Cited for its epidemiological insights on metabolic markers.

Kyaw Thein | Health Sciences | Best Researcher Award

Assist. Prof. Dr. Kyaw Thein | Health Sciences | Best Researcher Award

MD | Comprehensive Cancer Centers of Nevada – Central Valley | United States

Dr. Kyaw Zin Thein, MD, is a highly skilled Medical Oncologist and Hematologist currently practicing at the Central Valley Treatment Center – Twain, affiliated with the Comprehensive Cancer Centers of Nevada. He also serves as a Clinical Assistant Professor at Touro University Nevada (TUN) and the University of Nevada, Las Vegas (UNLV). His dedication to patient care, research, and education has solidified his reputation as a leader in precision oncology and hematology.

Profile

Scopus

Google scholar

Orcid

Strengths for the Awards

  • Impressive Academic and Clinical Training
    • Dr. Kyaw Zin Thein has a robust academic background, including advanced fellowships in hematology, oncology, and investigational cancer therapeutics at world-renowned institutions such as MD Anderson Cancer Center.
    • A double board-certified oncologist and hematologist with certifications valid through 2029, showcasing his extensive expertise and commitment to maintaining professional standards.
  • Research Contributions and Publications
    • Author of 53 peer-reviewed journal articles, demonstrating significant contributions to advancing knowledge in oncology and hematology.
    • Published book chapters on cutting-edge topics like poly (ADP-ribose) polymerase inhibitors and multidisciplinary paradigms for head and neck cancer, reflecting his thought leadership in the field.
  • Teaching and Mentorship
    • Active roles as Clinical Assistant Professor at UNLV and Touro University Nevada, contributing to medical education.
    • Mentorship of numerous trainees, ranging from medical students to fellows, highlighting his commitment to shaping the next generation of oncologists and researchers.
  • Leadership and Awards
    • Held leadership roles, including Chief Fellow, Chief Resident, and committee member positions at esteemed institutions.
    • Recipient of multiple awards, such as the ASH Abstract Achievement Award and Research Recognition Awards, underscoring his excellence in research and clinical practice.

Education 🎓

Dr. Thein completed his M.B., B.S. (Doctor of Medicine) at the Institute of Medicine 1, Yangon, Myanmar (2004–2010). His advanced training includes:

  • Residency in Internal Medicine at Kingsbrook Jewish Medical Center, NY (2012–2015).
  • Fellowship in Hematology & Medical Oncology at Texas Tech University Health Sciences Center, TX (2016–2019).
  • Advanced Fellowships in Investigational Cancer Therapeutics and Oncologic Emergency Medicine at the University of Texas MD Anderson Cancer Center (2015–2020).

Professional Experience 💼

Dr. Thein has held numerous prestigious positions:

  • Medical Oncologist/Hematologist, Central Valley Treatment Center, Nevada (2023–present).
  • Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University (OHSU) (2020–2023).
  • Chief Fellow, Texas Tech University Health Sciences Center (2018–2019).
  • Member of multiple professional committees, including the Knight Cancer Institute’s Data and Safety Monitoring Committee.

Research Interests On Health Sciences🔬

Dr. Thein’s research focuses on precision oncology, investigational cancer therapeutics, and immunotherapy. He has contributed extensively to advancing cancer care through his work on targeted therapies, combination regimens, and innovative diagnostic methods.

Awards & Recognitions 🏆

Dr. Thein has received numerous accolades, including:

  • ASH Abstract Achievement Award, American Society of Hematology (2016).
  • Research Recognition Awards from Kingsbrook Jewish Medical Center (2014, 2015).
  • Excellence in Education Award, Myanmar American Medical Education Society (2011).

Publications 📚

  • Copper deficiency anemia
    • Authors: ZW Myint, TH Oo, KZ Thein, AM Tun, H Saeed
    • Year: 2018
    • Citations: 298
  • 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
    • Authors: G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, et al.
    • Year: 2021
    • Citations: 136
  • Precision therapy for RET-altered cancers with RET inhibitors
    • Authors: KZ Thein, V Velcheti, BHM Mooers, J Wu, V Subbiah
    • Year: 2021
    • Citations: 112
  • Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
    • Authors: I El Majzoub, A Qdaisat, KZ Thein, MA Win, MM Han, K Jacobson, et al.
    • Year: 2019
    • Citations: 91
  • Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism
    • Authors: MA Win, KZ Thein, A Qdaisat, SCJ Yeung
    • Year: 2017
    • Citations: 83
  • The contemporary management of cancers of the sinonasal tract in adults
    • Authors: R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, et al.
    • Year: 2023
    • Citations: 74
  • Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
    • Authors: B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, et al.
    • Year: 2022
    • Citations: 74
  • Therapeutics targeting mutant KRAS
    • Authors: KZ Thein, AB Biter, DS Hong
    • Year: 2021
    • Citations: 55
  • Pernicious anemia: Pathophysiology and diagnostic difficulties
    • Authors: TW Htut, KZ Thein, TH Oo
    • Year: 2021
    • Citations: 52
  • Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy
    • Authors: KZ Thein, TW Htut, S Ball, S Swarup, A Sultan, TH Oo
    • Year: 2020
    • Citations: 45

Conclusion 🌟

Dr. Kyaw Zin Thein is a visionary leader in oncology and hematology, with a career distinguished by cutting-edge research, impactful teaching, and exceptional clinical care. His dedication to advancing cancer therapies and mentoring future medical professionals underscores his commitment to transforming cancer treatment and education worldwide.